Huntington's drug shows promise for speech and gait issues
NCT ID NCT04713982
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether deutetrabenazine can improve speech clarity and walking ability in people with Huntington disease. About 30 adults with early to moderate symptoms will take the drug and be evaluated using speech tests and motion capture technology. The goal is to see if this medication, already used for movement problems, can also ease these specific daily challenges.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States